Rachel Humphrey

Rachel Humphrey

Company: Black Diamond Therapeutics

Job title: Chief Medical Officer


BDTX-189: A MasterKey Inhibitor of EGFR and HER2 Exon 20 Insertion Mutations and Allosteric HER2 Mutations 12:00 pm

• The role of Black Diamond’s proprietary MAP platform for the identification and validation of allosteric EGFR and HER2 oncogenic driver mutations, including Exon 20 insertion mutations • Overview of the profile of BDTX-189, including a presentation of preclinical pharmacokinetic, safety, and anti-tumor activity data • The ongoing MasterKey-01 trial, a Phase 1/2 clinical trial…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.